ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ProKidney Corp (Nasdaq: PROK), a late clinical-stage biotech company specializing in cell therapy for chronic kidney disease (CKD), has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Bruce Culleton, M.D., will deliver a presentation on January 15, 2025, at 7:30am PST.
The company's management team will be available for one-on-one meetings during the event. Interested parties can access the live webcast through the 'Events' section of ProKidney's Investor Relations webpage at www.prokidney.com. A replay of the presentation will remain available for 90 days following the event.
ProKidney Corp (Nasdaq: PROK), una biotech in fase clinica avanzata specializzata in terapia cellulare per le malattie renali croniche (CKD), ha annunciato la sua partecipazione alla 43陋 Conferenza Annuale J.P. Morgan Healthcare. Il CEO Bruce Culleton, M.D., presenter脿 il suo intervento il 15 gennaio 2025, alle 7:30 PST.
Il team di gestione dell'azienda sar脿 disponibile per incontri individuali durante l'evento. Le parti interessate possono accedere al webcast dal vivo tramite la sezione 'Eventi' del sito web delle Relazioni con gli Investitori di ProKidney all'indirizzo www.prokidney.com. La registrazione della presentazione rimarr脿 disponibile per 90 giorni dopo l'evento.
ProKidney Corp (Nasdaq: PROK), una empresa biotecnol贸gica en etapa cl铆nica avanzada especializada en terapia celular para la enfermedad renal cr贸nica (ERC), ha anunciado su participaci贸n en la 43陋 Conferencia Anual J.P. Morgan Healthcare. El CEO Bruce Culleton, M.D., presentar谩 el 15 de enero de 2025, a las 7:30 a.m. PST.
El equipo directivo de la compa帽铆a estar谩 disponible para reuniones uno a uno durante el evento. Las partes interesadas pueden acceder a la transmisi贸n en vivo a trav茅s de la secci贸n 'Eventos' de la p谩gina web de Relaciones con Inversores de ProKidney en www.prokidney.com. Una repetici贸n de la presentaci贸n estar谩 disponible durante 90 d铆as despu茅s del evento.
ProKidney Corp (Nasdaq: PROK), 毵岇劚 鞁犾灔 歆堩櫂(CKD)鞚� 鞙勴暅 靹疙彫 旃橂鞐� 韸鬼檾霅� 鞛勳儊 雼硠臧� 電潃 靸濍獏瓿淀暀 須岇偓臧� 鞝�43須� J.P. Morgan Healthcare 旎嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. CEO 敫岆（鞀� 旎爤韱�(Dr. Bruce Culleton)鞚� 2025雲� 1鞗� 15鞚�, 鞓れ爠 7:30 PST鞐� 氚滍憸毳� 頃� 鞓堨爼鞛呺媹雼�.
須岇偓鞚� 瓴届榿歆� 韺�鞚� 頄夓偓 霃欖晥 鞚茧寑鞚� 須岇潣鞐� 彀胳劃頃� 靾� 鞛堨姷雼堧嫟. 甏�鞁� 鞛堧姅 雼轨偓鞛愲姅 www.prokidney.com鞚� ProKidney 韴瀽鞛� 甏�瓿� 鞗鬼帢鞚挫鞚� '鞚措菠韸�' 靹轨厴鞚� 韱淀暣 靸濎瓿勲ゼ 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟. 氚滍憸鞚� 鞛儩鞚� 頄夓偓 頉� 90鞚� 霃欖晥 鞝滉车霅� 瓴冹瀰雼堧嫟.
ProKidney Corp (Nasdaq: PROK), une entreprise biopharmaceutique en phase clinique avanc茅e sp茅cialis茅e dans la th茅rapie cellulaire pour les maladies r茅nales chroniques (CKD), a annonc茅 sa participation 脿 la 43猫me Conf茅rence Annuelle J.P. Morgan Healthcare. Le PDG Bruce Culleton, M.D., fera une pr茅sentation le 15 janvier 2025, 脿 7h30 PST.
L'茅quipe de direction de l'entreprise sera disponible pour des r茅unions individuelles pendant l'茅v茅nement. Les parties int茅ress茅es peuvent acc茅der au webcast en direct via la section '脡v茅nements' de la page Relations Investisseurs de ProKidney 脿 l'adresse www.prokidney.com. Un enregistrement de la pr茅sentation sera disponible pendant 90 jours suivant l'茅v茅nement.
ProKidney Corp (Nasdaq: PROK), ein sp盲tklinisches Biotech-Unternehmen, das sich auf zellulare Therapie bei chronischen Nierenerkrankungen (CKD) spezialisiert hat, hat seine Teilnahme an der 43. j盲hrlichen J.P. Morgan Healthcare Conference bekannt gegeben. CEO Bruce Culleton, M.D., wird am 15. Januar 2025, um 7:30 Uhr PST eine Pr盲sentation halten.
Das Management-Team des Unternehmens steht w盲hrend der Veranstaltung f眉r Einzelgespr盲che zur Verf眉gung. Interessierte Parteien k枚nnen 眉ber den Bereich 'Veranstaltungen' auf der Investor-Relations-Webseite von ProKidney unter www.prokidney.com auf das Live-Webcast zugreifen. Eine Aufzeichnung der Pr盲sentation bleibt 90 Tage nach der Veranstaltung verf眉gbar.
- None.
- None.
WINSTON-SALEM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK)听(鈥淧roKidney鈥�), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that ProKidney鈥檚 CEO, Bruce Culleton, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event.
| 43rd Annual J.P. Morgan Healthcare Conference | |
| Date: | January 15, 2025 |
| Time: | 7:30am PST |
| Format: | Presentation |
| Webcast: | |
| 听 | 听 |
The live webcast will also be accessible through the 鈥淓vents鈥� section of the Investor Relations tab within ProKidney鈥檚 website at . Following the completion of the event, a replay will be available for 90 days.
About ProKidney Corp.
ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney鈥檚 lead product candidate, rilparencel (also known as REACT庐), is a first-in-class, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit .
Investor Contacts:
ProKidney
Ethan Holdaway
LifeSci Advisors, LLC
Daniel Ferry
FAQ
When is ProKidney (PROK) presenting at the 2025 J.P. Morgan Healthcare Conference?
How long will ProKidney's (PROK) J.P. Morgan Conference presentation replay be available?
Where can investors watch ProKidney's (PROK) J.P. Morgan Healthcare Conference presentation?
What is ProKidney's (PROK) main focus in development?
Will ProKidney (PROK) management be available for individual meetings at the J.P. Morgan Conference?
